CHELSEA RAY: Open Payments
NPI 1023370624 · MUNISING, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$979 in 48 payments from 20 companies in 2025. Trend: 2023 $830 · 2024 $999 · 2025 $979
Food & beverage: $979
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 6 | $123 |
| Axsome Therapeutics, Inc. | 5 | $99 |
| GlaxoSmithKline, LLC. | 4 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $79 |
| Lilly USA, LLC | 4 | $78 |
| Novo Nordisk Inc | 4 | $70 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $65 |
| PFIZER INC. | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Merck Sharp & Dohme LLC | 2 | $43 |
Products named: JARDIANCE, OTEZLA, Auvelity, REXULTI, CAPLYTA, TRELEGY ELLIPTA, Rybelsus, PAXLOVID.
Industry payments across MI — which companies pay providers there.
